U.S. Pharmacist Weekly News
|
Elevated Suicide Rates of Pharmacists Versus General Population
|
|
Background information in a recent study advises that suicide is one of the leading causes of death worldwide, and estimates of suicide among health professionals are higher than the general population, with at least one risk factor appearing to be job stress. Learn more about these risk factors that lead pharmacists to take their own lives.
|
|
|
Transplant Patients on Tacrolimus and Paxlovid Experienced Adverse Reactions
|
|
|
Solid-organ transplant recipients are at higher risk of severe cases of COVID-19, but the use of new oral antivirals can be dangerous for those on tacrolimus, according to a new report in Open Forum Infectious Diseases. The authors described two cases where transplant recipients who were prescribed nirmatrelvir/ritonavir developed tacrolimus toxicity and required hospitalization. Read more.
|
|
Novel T2D Injectable Drug Approved by the FDA
|
|
|
Supplies of a novel, new molecular entity injectable type 2 diabetes (T2D) drug should be available in the United States in a few weeks. Tirzepatide injection, marketed as Mounjaro by Eli Lilly and Company, is a first-in-class medication that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide hormones involved in blood sugar control. Learn more about this novel drug.
|
|
|
Moderna Vaccine More Effective for Some Immunocompromised Patients
|
|
The two mRNA COVID-19 vaccines are not always equally effective, although the Moderna COVID-19 vaccine appears to be somewhat more efficacious. Find out why a new study suggests that the Moderna product might work better in patients receiving immunosuppression and how differential immunogenicity was highest in the most immunosuppressed participants—solid organ–transplant recipients receiving mycophenolic acid or mycophenolate mofetil.
|
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
.jpg)
.jpg)
